March 2025
1. YU Y, Gao X, Zhao H, Sun J, et al
   A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.
   Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-3217.
   

   >> Share

   
   December 2024
2. PRABAGAR MG, McQueney M, Bommireddy V, Siegel R, et al
   THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER.
   Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-1022.
   

   >> Share

   
   September 2024
3. CUI C, Zhang H, Yang C, Yin M, et al
   Inhibition of JNK Signaling Overcomes Cancer-Associated Fibroblast-Mediated Immunosuppression and Enhances the Efficacy of Immunotherapy in Bladder Cancer.
   Cancer Res. 2024 Sep 18. doi: 10.1158/0008-5472.CAN-24-0940.
   

   >> Share

   
   August 2024
4. KELLER PJ, Adams EJ, Wu R, Cote A, et al
   Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
   Cancer Res. 2024;84:2501-2517.
   

   >> Share

   
   July 2024
5. ZENG Y, Luo Y, Zhao K, Liu S, et al
   m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis.
   Cancer Res. 2024 Jul 24. doi: 10.1158/0008-5472.CAN-23-3703.
   

   >> Share

   
   
6. YANG Y, Suhasini AN, Jiang Z, Liu N, et al
   A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
   Cancer Res. 2024;84:2169-2180.
   

   >> Share

   
   May 2024
7. JONES RT, Scholtes M, Goodspeed A, Akbarzadeh M, et al
   NPEPPS Is a Druggable Driver of Platinum Resistance.
   Cancer Res. 2024;84:1699-1718.
   

   >> Share

   
   March 2024
8. HOSNI S, Kilian V, Klumper N, Gabbia D, et al
   Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
   Cancer Res. 2024;84:725-740.
   

   >> Share

   
   November 2023
9. ZHAO Y, Chen J, Zheng H, Luo Y, et al
   SUMOylation-driven mRNA circularization enhances translation and promotes lymphatic metastasis of bladder cancer.
   Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-2278.
   

   >> Share

   
   September 2023
10. OUYANG Y, Ou Z, Zhong W, Yang J, et al
    FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation.
    Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065.
    

    >> Share

    
    April 2023
11. OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al
    Correction: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    Cancer Res. 2023;83:1159.
    

    >> Share

    
    March 2023
12. ZHUANG J, Shen L, Li M, Sun J, et al
    Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance.
    Cancer Res. 2023 Mar 20:CAN-22-2213. doi: 10.1158/0008-5472.CAN-22-2213.
    

    >> Share

    
    
13. ZHANG L, Li Y, Zhou L, Zhou H, et al
    The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response.
    Cancer Res. 2023 Mar 20:CAN-22-2485. doi: 10.1158/0008-5472.CAN-22-2485.
    

    >> Share

    
    
14. XIE R, Cheng L, Huang M, Huang L, et al
    NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer.
    Cancer Res. 2023 Mar 20:CAN-22-2233. doi: 10.1158/0008-5472.CAN-22-2233.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share